Travere Therapeutics, Inc. (TVTX)
$52.02-0.21%Close
SELLCRISIS · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $4.8B
- Beta
- 1.06
- P/E (TTM)
- -124.40
- Short % float
- 14.01%
- Days to cover
- 7.2
- SI change
- -2.3%
- 1W
- -9.80%
- 1M
- -21.38%
- vs SPY 1W
- -10.22%
- vs SPY 1M
- -23.44%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on TVTX?
- LOPJLB’s latest quantitative signal on Travere Therapeutics, Inc. (TVTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is TVTX in?
- Travere Therapeutics, Inc. (TVTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Travere Therapeutics, Inc. (TVTX) do?
- Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 t…